COVID-19
Although some may be hopeful that the end of the COVID-19 pandemic is nearby, millions still are facing their own lifelong version of the pandemic.
COVID-19 cases are soaring in China, Hong Kong, the U.K. and parts of Europe. A recent Demy-Colton Virtual Salon explored what we can expect in the near future.
Seattle-based Icosavax’s stock plunged 50% after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
Novavax announced today that its protein-based Covid-19 vaccine, NVX-CoV2373, is included in two new clinical trials that will evaluate the vaccine as a potential Covid booster.
A recent study in mice was able to halt memory decay in a model of Alzheimer’s disease. Another study found that even mild infection increased the risk of new-onset type 2 diabetes, although the risk increased with the severity of COVID-19.
BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age.
Study after study shows the disease comes with an increased risk of a number of health problems, including diabetes. One of the best ways to avoid those risks is to get vaccinated.
Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.
Albert Bourla, Pfizer’s CEO, took home a salary of $1.69 million in 2021. To Pfizer, he’s undoubtedly worth it, having led the company to its COVID-19 vaccine success.
PRESS RELEASES